Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its underwritten public offering of 3,000,000 shares of its Class A common stock at a price to the public of $72.00 per share.
Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.
The V&E corporate team was led by partner Robert Kimball (Picture) with assistance from senior associate Katherine Frank and associates Desi Baca and Grace-Ann Duquette. Partner Jim Meyer and associate Glen Ellsworth advised on tax issues.
Involved fees earner: Robert Kimball – Vinson & Elkins LLP; Katherine Terrell Frank – Vinson & Elkins LLP; Desiree Baca – Vinson & Elkins LLP; Grace-Ann Duquette – Vinson & Elkins LLP; James Meyer – Vinson & Elkins LLP; Glen Ellsworth – Vinson & Elkins LLP;
Law Firms: Vinson & Elkins LLP;
Clients: Reata Pharmaceuticals, Inc.;